Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cipaglucosidase Alfa→

Cipaglucosidase Alfa Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2359727-71-0
Molecular formula
C4489H6817N1197O1298S32
Molecular weight
99350 g/mol
Drug class
Recombinant human acid alpha-glucosidaseenzyme replacement therapy biologic
Mechanism of action
Replaces deficient lysosomal acid alpha-glucosidase (GAA), enabling lysosomal hydrolysis of glycogen to glucose. The product is used with miglustat, which helps stabilise the enzyme and support cellular uptake.
Indications / reported uses
  • Long-term enzyme replacement therapy in adults with late-onset Pompe disease (GAA deficiency), in combination with miglustat, under the applicable product authorisation

Sources: EMA EPAR — Pombiliti (cipaglucosidase alfa) · US DailyMed — POMBILITI · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cipaglucosidase Alfa Environmental Risk Assessment (ERA) (the Cipaglucosidase Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.